Key questions arise from the announcement;
1. Would a more efficient delivery system improve drug activity for DMD patients?
2. Given that the drug appears to have a good safety profile, would the addition of the CPP compromise drug safety?
These questions will be addressed by the expanded collaboration outlined in the announcement. Some of the language in the announcement may provide an interim insight.
- "a key challenge with these drugs is to optimise their delivery into cells to make treatments much more effective"
- "this study further validates our cell-penetrating Phylomers for their ability to deliver different therapeutic cargoes inside cells more safely and with greater efficiencies" - italics added.
Just an interesting aside, the clinical trial of Sarepta's DMD drug eteplirsen is generating a lot of interest. According to John Carroll from FierceBiotech its fate is 'one of the most closely watched agency deadlines of the decade'.
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)